Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: Regulation by SOCS

Journal of Clinical Investigation

Volumn 110, Issue 10, 2002, Pages 1503-1513

  Hong, Feng ^a   Jaruga, Barbara ^a   Kim, Won Ho ^a   Radaeva, Svetlana ^a   El Assal, Osama N ^a   Tian, Zhigang ^a   Nguyen, Van Anh ^a   Gao, Bin ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CONCANAVALIN A; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 6; PROTEIN BCL XL; PROTEIN SOC1; PROTEIN SOC3; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DOWN REGULATION; GENE ACTIVATION; GENE DISRUPTION; GENE EXPRESSION REGULATION; GENE INDUCTION; HEPATITIS; KNOCKOUT GENE; LIVER CELL; LIVER INJURY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

EID: 0036854891     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0215841     Document Type: Article

References (59)

1. Kita, H., Mackay, I.R., Van De Water, J., and Gershwin, M.E. 2001. The lymphoid liver: Considerations on pathways to autoimmune injury. Gastroenterology. 120:1485-1501.
2. Heneghan, M.A., and McFarlane, I.G. 2002. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology. 35:7-13.
3. Bogdanos, D.P., Mieli-Vergani, G., and Vergani, D. 2000. Virus, liver and autoimmunity. Dig. Liver Dis. 32:440-446.
4. Rehermann, B., and Chisari, F.V. 2000 Cell-mediated immune response to the hepatitis C virus. Curr. Top. Microbiol. Immunol. 242:299-325.
5. Chedid, A., et al. 1993. Cell-mediated hepatic injury in alcoholic liver disease. Veterans Affairs Cooperative Study Group 275. Gastroenterology. 105:254-266.
6. Lohr, H.F., et al. 1996. Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis. Hepatology. 24:1416-1421.
7. Napoli, J., Bishop, G.A., McGuinness, P.H., Painter, D.M., and McCaughan, G.W. 1996. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology. 24:759-765.
8. Rosen, H.R., et al. 2002. Frequencies of HCV-specific effector CD4+ T cells by flow cytometry: Correlation with clinical disease stages. Hepatology. 35:190-198.
9. Chang, K.M., et al. 2001. Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 33:267-276.
10. Chisari, F.V. 1997. Cytotoxic T cells and viral hepatitis. J. Clin. Invest. 99:1472-1477.
11. Tiegs, G., Hentschel, J., and Wendel, A. 1992. A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J. Clin. Invest. 90:196-203.
12. Kaneko, Y., et al. 2000. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis. J. Exp. Med. 191:105-114.
13. Fiorucci, S., et al. 2000. NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology. 118:404-421.
14. Tagawa, Y., Sekikawa, K., and Iwakura, Y. 1997. Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: Role for IFN-gamma in activating apoptosis of hepatocytes. J. Immunol. 159:1418-1428.
15. Wolf, D., et al. 2001. TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR1-relevance for concanavalin A-induced hepatitis. J. Immunol. 166:1300-1307.
16. Schindler, C. 1999. Cytokines and JAK-STAT signaling. Exp. Cell Res. 253:7-14.
17. Darnell, J.E., Jr., Kerr, I.M., and Stark, G.R. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
18. Ihle, J.N. 1996. STATs: Signal transducers and activators of transcription. Cell. 84:331-334.
19. Leonard, W.J. 2001. Role of Jak kinases and STATs in cytokine signal transduction. Int. J. Hematol. 73:271-277.
20. Chen, X.P., Losman, J.A., and Rothman, P. 2000. SOCS proteins, regulators of intracellular signaling. Immunity. 13:287-290.
21. Nicola, N.A., et al. 1999. Negative regulation of cytokine signaling by the SOCS proteins. Cold Spring Harb. Symp. Quant. Biol. 64:397-404.
22. Naka, T., Fujimoto, M., and Kishimoto, T. 1999. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem. Sci. 24:394-398.
23. Kamiya, A., et al. 1999. Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer. EMBO J. 18:2127-2136.
24. Baumann, H., and Gauldie, J. 1994. The acute phase response. Immunol. Today 15:74-80.
25. Cressman, D.E., et al. 1996. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 274:1379-1383.
26. Kovalovich, K., et al. 2000. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology. 31:149-159.
27. Kovalovich, K., et al. 2001. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J. Biol. Chem. 276:26605-26613.
28. Hong, F., et al. 2002. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: Involvement of induction of Bcl-2 and Bcl-x(L) proteins. Oncogene. 21:32-43.
29. Meraz, M.A., et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 84:431-442.
30. Durbin, J.E., Hackenmiller, R., Simon, M.C., and Levy, D.E. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 84:443-450.
31. Radaeva, S., et al. 2002. Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes. Gastroenterology. 122:1020-1034.
32. Huang, Y.Q., Li, A.J., and Karpatkin, S. 2000. Thrombin inhibits tumor cell growth in association with up-regulation of p21(waf/cip1) and caspases via a p53-independent, STAT-1-dependent pathway. J. Biol. Chem. 275:6462-6468.
33. Grad, J.M., Zeng, X.R., and Boise, L.H. 2000. Regulation of Bcl-xL: A little bit of this and a little bit of STAT. Curr. Opin. Oncol. 12:543-549.
34. Han, Z., Hendrickson, E.A., Bremner, T.A., and Wyche, J.H. 1997. A sequential two-step mechanism for the production of the mature p17:p12 form of caspase-3 in vitro. J. Biol. Chem. 272:13432-13436.
35. Kusters, S., Gantner, F., Kunstle, G., and Tiegs, G. 1996. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology. 111:462-471.
36. Mizuhara, H., et al. 1994. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6. J. Exp. Med. 179:1529-1537.
37. Takeda, K., et al. 2000. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. USA. 97:5498-5503.
38. Alexander, W.S., et al. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 98:597-608.
39. Naka, T., et al. 2001. SOCS-1/SS1-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity. 14:535-545.
40. Ivashkiv, L.B., Schmitt, E.M., and Castro, A. 1996. Inhibition of transcription factor Stat1 activity in mononuclear cell cultures and T cells by the cyclic AMP signaling pathway. J. Immunol. 157:1415-1421.
41. Kunstle, G., et al. 1999. Concanavalin A hepatotoxicity in mice: Tumor necrosis factor-mediated organ failure independent of caspase-3-like protease activation. Hepatology. 30:1241-1251.
42. Chen, D., et al. 2001. CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: Evidence for involvement of CD44 in activation-induced cell death. J. Immunol. 166:5889-5897.
43. Kim, K.M., et al. 2000. A broad-spectrum caspase inhibitor blocks concanavalin A-induced hepatitis in mice. Clin. Immunol. 97:221-233.
44. Ksontini, R., et al. 1998. Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis. J. Immunol. 160:4082-4089.
45. Tagawa, Y., Kakuta, S., and Iwakura, Y. 1998. Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Eur. J. Immunol. 28:4105-4113.
46. Kano, A., Haruyama, T., Akaike, T., and Watanabe, Y. 1999. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes. Biochem. Biophys. Res. Commun. 257:672-677.
47. Mizuhara, H., et al. 1996. Critical involvement of interferon gamma in the pathogenesis of T-cell activation-associated hepatitis and regulatory mechanisms of interleukin-6 for the manifestations of hepatitis. Hepatology. 23:1608-1615.
48. de la Coste, A., et al. 1999. Differential protective effects of Bcl-xL and Bcl-2 on apoptotic liver injury in transgenic mice. Am. J. Physiol. 277:G702-G708.
49. Nicholson, S.E., et al. 1999. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18:375-385.
50. Saito, H., et al. 2000. IFN regulatory factor-1-mediated transcriptional activation of mouse STAT-induced STAT inhibitor-1 gene promoter by IFN-gamma. J. Immunol. 164:5833-5843.
51. Starr, R., et al. 1997. A family of cytokine-inducible inhibitors of signaling. Nature. 387:917-921.
52. Campbell, J.S., et al. 2001. Expression of suppressors of cytokine signaling during liver regeneration. J. Clin. Invest. 107:1285-1292.
53. Koziel, M.J. 1999. Cytokines in viral hepatitis. Semin. Liver Dis. 19:157-169.
54. Sobue, S., et al. 2001. Th1/Th2 cytokine profiles and their relationship to clinical features in patients with chronic hepatitis C virus infection. J. Gastroenterol. 36:544-551.
55. Cui, W., Dong, Y., Fang, F., and Li, G. 1998. Tumor necrosis factor alpha, interleukin-6, interleukin-8, and interferon alpha in children with viral hepatitis. J. Tongji Med. Univ. 18:247-249.
56. al-Wabel, A., al-Janadi, M., and Raziuddin, S. 1993. Cytokine profile of viral and autoimmune chronic active hepatitis. J. Allergy Clin. Immunol. 92:902-908.
57. Maggiore, G., De Benedetti, F., Massa, M., Pignatti, P., and Martini, A. 1995. Circulating levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in children with autoimmune hepatitis. J. Pediatr. Gastroenterol. Nutr. 20:23-27.
58. Martinez, O.M., Villanueva, J.C., Gershwin, M.E., and Krams, S.M. 1995. Cytokine patterns and cytotoxic mediators in primary biliary cirrhosis. Hepatology. 21:113-119.
59. McClain, C.J., Barve, S., Deaciuc, I., Kugelmas, M., and Hill, D. 1999. Cytokines in alcoholic liver disease. Semin. Liver Dis. 19:205-219.